All In Biotech

Free tool

FAERS Monitor: Akeega

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216793 or its brand name (Akeega, Abiraterone Acetate, Niraparib Tosylate). Reports on generic versions are filed under their own applications.

Reports

62

Serious

45

73% of reports

Hospitalization

19

Death reported

12

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use6
  • constipation4
  • decreased appetite4
  • fatigue4
  • nausea4
  • product ineffective for unapproved use4
  • prostatic specific antigen increased4
  • abdominal pain upper3
  • blood pressure increased3
  • death3
  • dizziness3
  • drug ineffective3
  • malaise3
  • pancytopenia3
  • adverse event2

Reports by year received

View as table
YearReports
202425
202516
202621

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,097 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product ineffective for unapproved useSignal4511.0197.91,556
prostatic specific antigen increasedSignal498.538.2295
pancytopeniaSignal318.26.033
adverse event27.41.96
blood pressure increasedSignal36.72.29
constipationSignal46.22.413
decreased appetiteSignal45.82.312
abdominal pain upperSignal34.91.66
off label use62.31.13
malaise32.30.81
dizziness32.00.71
fatigue41.70.71
nausea41.70.71
death31.20.40
drug ineffective30.80.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.